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Abstract: The Hippo pathway is an evolutionally conserved pathway and plays an important role in regulating tissue 
hemostasis and organ size control. Deregulation of the Hippo pathway is implicated in various human digestive sys-
tem tumors. The past two decades have witnessed the discovery and elucidation of key signaling components and 
molecular mechanisms of the Hippo pathway. Among these, the signaling transducers YAP/TAZ are in the center of 
this complex network to sense and respond to extracellular cues such as cell contact, matrix stiffness and growth 
factors. In this review, we summarize the biological and clinical significance of Hippo-YAP signaling in the digestive 
system tumors, and explore the novel therapeutic strategies for targeting Hippo-YAP signaling.   
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Introduction
Originally discovered through Drosophila genet-
ic screen for molecules regulating organ size, 
the Hippo-YAP pathway has emerged as an 
evolutionally conserved signaling pathway to 
regulate various biological functions including 
tissue homeostasis, regeneration and tumori-
genesis [1, 2]. The first Hippo pathway gene 
identified was the NDR family protein kinase 
Warts (homologous to mammalian gene Large 
tumor suppressor kinase 1/2 [Lats1/2]) [3, 4]. 
Inactivation of Warts gene leads to dramatic 
tissue overgrowth in Drosophila. Subsequently, 
additional Hippo pathway components, includ-
ing Salvador (homologous to mammalian gene 
Sav1, also known as WW45) [5, 6], Ste20-like 
protein kinase Hippo (homologous to mamma-
lian gene MST1/2) [7-11], and Mats (homolo-
gous to mammalian gene Mob1) [12], were 
identified through similar genetic approaches. 
The identification of Yki (homologous to mam-
malian gene Yes-Associated Protein [YAP] and 
Transcriptional Co-activator with PDZ-binding 
Motif [TAZ]), published in a seminal article in 
2005 [13], completed the missing link in the 
Hippo signaling kinase cascade. In mammals, 
the classical pathway proceeds as follows: 
Mst1/2 kinase binds its cofactor Sav1 (also 
known as WW domain containing adaptor 45, 
or WW45), and this complex phosphorylates 
and activates Lats1/2 kinase. Lats1/2 kinase 
then binds its cofactor Mob1, which phosphory-
lates and inactivates transcription coactivators 
YAP and TAZ. In the setting of signaling deregu-
lation, YAP is dephosphorylated and translocate 
to nucleus. In conjunction with its transcription 
factor TEA domain family members (TEAD 1-4) 
[14-16], nuclear YAP functions as a potent tran-
scription coactivator to promote target gene 
transcription (Figure 1). Besides transcription 
factor TEAD, the nuclear events for Hippo-YAP 
signaling also involve Vestigial-like family tran-
scriptional coactivator VGLL 1-4. In the Hippo 
pathway, VGLL could compete with YAP/TAZ for 
TEAD binding [17]. The dramatic tissue over-
growth phonotype observed in Hippo pathway 
inactivation in Drosophila has been attributed 
to the ability of activated YAP to induce tran-
scription of genes that promote cell growth and 
proliferation, as well as inhibition of apoptosis 
[7].    
Multiple membrane-associated cytoskeletal 
proteins, including Merlin (homologous to mam-
malian gene NF2) and Expanded [18], Kibra 
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[19-21], and Fat [22-25], have been identified 
as upstream components and regulators of 
Hippo-YAP signaling pathway. These upstream 
components provide important clues to answer-
ing the ultimate question: how is Hippo-YAP sig-
naling regulated by environmental cues for 
tumor initiation, progression and metastasis? 
The first clue for this question comes from cell-
cell contact inhibition, a well-known phenome-
non in which cells cease proliferation once they 
contact another cell [26]. It is a common belief 
that cancer cells have the ability to escape 
from this barrier to achieve uncontrolled growth 
[27]. Phosphorylation and inactivation of YAP 
through the Hippo pathway plays an important 
role to control cell growth and proliferation 
upon cell contact [28]. At low cell density, YAP is 
active and predominantly localized in the nuclei 
to promote target gene transcription. High cell 
density, on the other hand, leads to Hippo path-
way-dependent YAP phosphorylation and cyto-
plasmic translocation for its deactivation [28]. 
The interaction between YAP and alpha-catenin, 
a critical cell-cell junction component and cell 
density sensor in the skin, has been demon-
strated in this process to control epidermal 
stem cell proliferation and tumorigenesis [29]. 
Cell density and NF2 could also control tran-
scription factor TEAD activity through regula-
tion of its palmitoylation status [30].
The Hippo-YAP signaling also plays an impor-
tant role in matrix stiffening-associated mecha-
notransduction. Frequently, tumors are stiffer 
than the surrounding benign tissue, largely due 
to increased fibrosis, interstitial pressure and 
angiogenic blood flow shear stress [31, 32]. 
Mechanotransduction is the concept that the 
cancer and stromal cells can sense matrix stiff-
ening and transduce this mechanical force to 
promote tumorigenic biochemical pathways for 
cell cycle progression, epithelial-mesenchymal 
transition, cell motility and metastasis. YAP is 
Figure 1. Schematic of Hippo-YAP signaling. When Hippo signaling is on, NF2 recruits Lats1/2 kinase to the mem-
brane. Mst1/2 kinase will then phosphorylate Lats1/2 kinase, which leads to phosphorylation, cytoplasmic reten-
tion, and subsequent ubiquitination and degradation of YAP. When Hippo signaling is off, YAP translocates to the 
nucleus and competes with VGLL for TEAD binding to regulate target gene expression with resultant anti-apoptosis 
and pro-proliferation effects.
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essential for tissue tension and morphogenesis 
during development [33]. Activation of the YAP 
is also a signature feature of cancer-associated 
fibroblasts (CAFs), and YAP-dependent matrix 
remodeling is required for CAFs to promote can-
cer cell invasion and angiogenesis [34].
In the past decade, the combined efforts of 
genetics and biochemistry have furthered our 
understanding of this important signaling path-
way. With the advances in sequencing technol-
ogy, it has become evident that the Hippo-YAP 
signaling pathway is frequently deregulated in 
different human cancers.  In this review, we will 
focus on its role in gastrointestinal, pancreatic 
and hepatic tumorigenesis.
Hippo-YAP signaling in esophageal cancer
Esophageal cancer is the seventh most com-
mon cancer worldwide. It is also the sixth most 
common cause for cancer-associated death 
[35]. Esophageal squamous cell carcinoma is 
the most prevalent esophageal cancer world-
wide, with a high incidence in developing coun-
tries. In the United States, even with decreas-
ing incidence of esophageal squamous cell 
carcinoma, the prevalence, incidence and 
associated mortality of esophageal cancer 
(adenocarcinoma) have been increasing over 
the past several decades, largely due to the 
pandemic of obesity and associated acid reflux 
[36].  
Frequent inactivating mutations of the Hippo-
YAP signaling, including mutations in AJUBA, 
FAT1-4, STK3, LATS1 and YAP, have been identi-
fied and validated in roughly half of the esopha-
geal squamous cell carcinoma cases [37, 38], 
supporting the critical role of the Hippo-YAP sig-
naling in the tumorigenesis of esophageal 
squamous cell carcinoma. The Cancer Genome 
Atlas (TCGA) Research Network detected high-
er rates of YAP (11q22.1) amplification and 
deletion of VGLL4, a negative regulator of 
Hippo-YAP signaling, in esophageal squamous 
cell carcinoma [39]. This study also demon-
strated the strong resemblance of esopha- 
geal adenocarcinoma with the chromosomally 
unstable variant of gastric adenocarcinoma 
[39].
Unlike esophageal squamous cell carcinoma, 
the involvement of the Hippo-YAP pathway in 
the development of esophageal adenocarcino-
ma is less clear. One study reported increased 
cytoplasmic and nuclear YAP expression in 
esophageal high-grade dysplasia and adeno-
carcinoma [40].  Preliminary data from our 
investigations also suggests that Hippo signal-
ing effector YAP plays critical roles in the pro-
gression of neoplasia associated with Barrett’s 
esophagus (BE), a precursor lesion of esopha-
geal adenocarcinoma that is more commonly 
seen in patients with longstanding gastro-
esophageal reflux disease. YAP expression is 
absent on the surface of benign esophageal 
columnar epithelium (Figure 2A), and is only 
weakly expressed in the deep crypts of benign 
esophageal mucus glands and non-dysplastic 
BE glands. In contrast, BE with high-grade dys-
plasia (Figure 2B) and esophageal adenocarci-
noma show significantly increased YAP expres-
sion (Figure 2C). These data support a potential 
role of Hippo-YAP signaling in the tumorigenesis 
of esophageal adenocarcinoma. 
Hippo-YAP signaling in gastric cancer
Gastric cancer is the fifth most common cancer 
and the fourth most common cause of cancer-
associated death worldwide [35]. With adeno-
carcinoma being the most common cancer 
type, gastric cancer has a clear relationship 
with long-standing chronic inflammation [41]. 
The common environmental factors include 
infectious agents such as Helicobacter pylori 
(HP) and Epstein-Barr virus (EBV), tobacco 
use, and dietary factors. HP eradication could 
reduce the risk of gastric adenocarcinoma [42]. 
Based on TCGA database, Hippo-YAP pathway 
is positively associated with HP infection [43]. 
Infection with cytotoxin-associated gene A 
(CagA) positive HP is the strongest risk factor 
for the development of gastric adenocarcino- 
ma [44, 45]. CagA+ HP infection significantly 
increased YAP expression in gastric epithelial 
cells, as compared with CagA- HP strain. 
Furthermore, CagA promotes epithelial mesen-
chymal transition in gastric carcinogenesis 
through Hippo-YAP pathway [46].
Multiple studies also confirm that the expres-
sion of YAP is significantly increased in gastric 
adenocarcinoma [47-49] (Figure 2D), with high-
er levels of cytoplasmic YAP in the early tumor 
stages and higher levels of nuclear YAP in the 
advanced tumor stages. Nuclear YAP accumu-
lation is associated with poor survival, espe-
cially in patients with early-stage gastric cancer 
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[50]. YAP mediates peritoneal carcinomatosis 
in advanced gastric adenocarcinoma patients 
[51]. Oncoprotein Myc has been identified as a 
key downstream target of YAP to initiate gastric 
tumorigenesis [52]. Up-regulation of YAP signifi-
cantly correlates with HP infection status and 
gastric cancer progression including tumor size 
and tumor stage. On the contrary, the transcrip-
tion levels of VGLL4, a negative regulator of 
Hippo signaling, were downregulated in 61% of 
gastric cancer samples, with inverse correla-
tion with gastric cancer progression (tumor 
size, tumor stage and lymph node metastasis) 
[53]. The YAP/VGLL4 ratio has the potential to 
serve as a biomarker for gastric cancer. 
In a study of 86 patients with advanced gastric 
cancer who received first-line chemotherapy, a 
significant association between nuclear TAZ 
expression and Wnt mutations was noted. The 
patients with tumors harboring a signature of 
combined nuclear TAZ expression and Wnt 
mutations had significantly increased risk of 
disease progression and poor overall survival 
[54]. Interestingly, the patients with tumors har-
boring a different signature (combined YAP 
expression and TP53 mutations) had favorable 
survival outcomes that is linked to the adminis-
tration of first-line chemotherapy [55]. 
Hippo-YAP signaling in colorectal cancer
Colorectal cancer is the third most common 
cancer and the second leading cause of cancer 
death in the United States [35]. Colorectal can-
cers can be divided into 3 major categories 
based on their unique molecular signatures: 
chromosomal instability pathway (84%) involv-
ing molecular alterations of APC, TP53, KRAS, 
SMAD and PIK3CA; microsatellite instability 
(MSI) hypermutant pathway (13%) involving the 
mismatch repair genes MLH1 and MSH2; ultra-
mutant pathway (3%) involving POLE gene [56]. 
Adenomatous polyposis coli (APC) alterations 
are the most common molecular events for the 
colorectal cancer, mostly through conventional 
adenoma-carcinoma sequence [57]. APC is 
one of the key players in the Wnt pathway, a 
critical signaling pathway in regulating intesti-
nal stem cell proliferation, differentiation and 
cell-fate decisions. Loss-of-function APC gene 
mutations lead to activation of Wnt pathway 
through accumulation of nuclear β-catenin. The 
cross-talk between Hippo and Wnt pathway 
plays important roles during intestinal regener-
ation, homeostasis and tumorigenesis [58]. 
The interactions of these two important path-
ways appear complex, multi-layered, and con-
text-dependent. In the nucleus, a β-catenin YAP 
complex is essential to the transformation and 
survival of β-catenin-dependent colon cancers 
[59]. However, in the cytoplasm, YAP/TAZ can 
function as negative regulators of Wnt/β- 
catenin signaling [60-62]. On the other hand, 
Wnt-APC pathway negatively regulates YAP 
function through β-catenin destruction com-
Figure 2. YAP expression in various digestive system tumors. (A-C) YAP expression in Barrett’s esophagus and 
esophageal adenocarcinoma. A. Negative YAP expression in benign esophageal columnar epithelium (×200); B. 
YAP expression in Barrett’s esophagus with high-grade dysplasia, note the increased YAP expression extending to 
surface epithelium (×200); C. YAP expression in esophageal adenocarcinoma, note the sharp transition between 
non-dysplastic mucosa and carcinoma (×200); D. YAP expression in gastric adenocarcinoma (×100); E. YAP expres-
sion in colorectal adenocarcinoma (×100); F. YAP expression in pancreatic ductal adenocarcinoma (×100). 
Hippo pathway in digestive system tumors
2499 Am J Cancer Res 2021;11(6):2495-2507
plex [61]. Additionally, APC can function as a 
scaffold protein to promote Hippo signaling and 
to restrict YAP activity [63]. Upon APC deficien-
cy, YAP/TAZ and β-catenin are required for 
intestinal crypt overgrowth and adenoma for-
mation [61, 63].
In the normal colon tissue, YAP is predominant-
ly expressed in the basal crypt zones where the 
intestinal progenitor cells are located. YAP is 
critical for intestinal regeneration and tumori-
genesis [64, 65]. Colonic adenocarcinoma tis-
sues have significantly elevated YAP protein 
expression in both the cytoplasm and nucleus 
[66] (Figure 2E). Elevated protein expression 
levels of YAP and TAZ are independent predic-
tors of poor prognosis and are positively corre-
lated with tumor stage, nodal status, and 
metastasis [66-69]. Elevated YAP protein 
expression, together with high plasma carcino-
embryonic antigen (CEA) level, are potential 
prognostic biomarkers in patients with early-
stage colorectal cancer [68]. Consistently, posi-
tive expression of VGLL4, combined with low 
YAP expression, is an independent good prog-
nostic factor in colorectal cancers [70]. 
Although YAP has well been accepted as a 
potent oncoprotein, dual roles of YAP in colorec-
tal cancer have been proposed, and there are 
multiple lines of evidence that YAP may also 
function as tumor suppressor, presumably in a 
context-dependent manner [71]. One example 
is its negative regulation of Wnt signaling. 
During intestinal regeneration, loss of YAP 
causes Wnt pathway hyperactivation, resulting 
in intestinal stem cell expansion, as well as 
ectopic crypt and microadenoma formation 
[62]. Alternatively, YAP is able to induce DNA 
damage-associated apoptosis through p73 
transcription factor [72-74]. Complete loss of 
YAP expression was correlated with aggressive 
clinical behaviors, including larger tumor size, 
higher tumor stage, and worse overall survival, 
and therefore represented an aggressive sub-
type of colorectal cancer [75]. The proposed 
tumor suppressor function of YAP might also 
play an important role in chronic colitis-associ-
ated colorectal cancer (CAC). In a recent study, 
our group has identified a subgroup of CAC with 
double negative expression of YAP and CDX2 
that is more frequently seen in younger patients 
(mean age of 45.3 years) with higher pathologi-
cal tumor stage and nodal metastasis [76].
Hippo-YAP signaling in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC), the 
most common form of pancreatic cancer, is 
one of the most aggressive cancers and ranks 
the seventh of all cancer-associated death 
[35]. Through next-generation sequencing, 
recurrent molecular alterations have been 
found in PDAC, with the oncogenic mutations of 
KRAS and loss-of-function mutation/deletion of 
tumor suppressor genes TP53, SMAD4 and 
CDKN2A (P16) being the most common [77]. 
Oncogenic mutations of KRAS are present in 
the majority of human PDAC cases, and target-
ing KRAS pharmacologically has a great clinical 
potential for the treatment of pancreatic can-
cer. Two elegant studies have independently 
identified YAP as a central driver to compen-
sate for the loss of KRAS signaling and to 
sustain tumor maintenance in an advanced 
PDAC mouse model [78, 79]. In a KRAS-mutant 
mouse model, YAP is also required for pancre-
atitis-induced acinar-to-ductal metaplasia, a 
precursor of pancreatic intraepithelial neopla-
sia that can progress to PDAC [80]. 
YAP is highly expressed in PDAC [79, 81-83] 
(Figure 2F). In fact, YAP is the top upregulated 
protein in PDAC samples on mass spectrome-
try-based proteomics [84]. Expression level of 
YAP is an independent predictor of poor overall 
survival (OS), disease-free survival (DFS) and 
liver metastasis [83-85], partially through its 
ability to promote transcription of target genes 
involved in the remodeling of pancreatic tumor 
microenvironment. YAP can also modulate the 
tumor immune microenvironment in PDAC by 
promoting the expression of cytokines/chemo-
kines that recruit and differentiate myeloid-
derived suppressor cells [86]. Therefore, YAP/
TAZ is at the center of a signaling network that 
is crucial for the development and progression 
of PDAC [87].
Hippo-YAP signaling in liver cancer
Liver cancer is the sixth most common cancer 
and the third leading cause of cancer-related 
death worldwide [35]. Hepatocellular carcino-
ma (HCC) is the most common primary liver 
cancer, and its major risk factors include viral 
infection (hepatitis B or C virus), alcohol abuse, 
obesity and iron overload, among others [88]. 
Due to its high degree of heterogeneity, HCC 
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remains a challenge for actionable molecular 
subtyping.  
During the past decade, Hippo-YAP signaling 
has emerged as a key pathway for the normal 
liver homeostasis maintenance, as well as the 
initiation and progression of liver cancer. In 
mouse model, liver-specific deletion of Hippo 
pathway tumor suppressor components NF2 
[89], Mst1/2 [90-92], Sav1 [92, 93], Mob1 [94] 
and Lats1/2 [95], or conditional overexpres-
sion of YAP in the liver [96] all leads to hepato-
megaly and liver cancer formation. The liver 
tumors developed in these mouse model 
include hepatic adenoma, HCC and intrahepat-
ic cholangiocarcinoma (iCC). Interesting, het-
erozygosity of YAP is sufficient to suppress 
hepatomegaly and HCC formation in those 
mouse models, supporting YAP/TAZ as poten-
tial therapeutic targets for HCC. Besides its 
function to regulate cellular proliferation and 
organ size, Hippo-YAP signaling also plays a 
critical role by influencing cell fates in the liver. 
YAP could induce a ductal fate in hepatocytes 
by dedifferentiating hepatocytes into progeni-
tor cells [97]. These findings lay the groundwork 
for regenerative medicine of liver disease and 
liver cancer through the manipulation of Hippo-
YAP signaling. 
The role of Hippo-YAP signaling in liver tumori-
genesis is quite complex, even with multiple 
lines of evidence demonstrating the potent 
oncogenic activity of YAP/TAZ. In a recent 
Science article, Moya et al. have revealed an 
unexpected non-autonomous tumor suppres-
sor function of YAP/TAZ in liver cancer [98]. 
Overexpression of YAP in peritumoral hepato-
cytes triggered regression of primary liver 
tumors and melanoma-derived liver metasta-
ses, and deletion of YAP/TAZ in peritumoral 
hepatocytes accelerated liver tumor growth. 
These interesting findings support a “cell com-
petition” theory originally proposed in a 
Drosophila study [99], that during interaction 
between tumor cells and their surrounding tis-
sue, the cell with low YAP/TAZ level will become 
the “loser” and be eliminated through cell-cell 
competition by the “winner”, the cell with high 
YAP/TAZ level. 
In human HCC, YAP overexpression is signifi-
cantly associated with poor tumor differentia-
tion and high serum alpha-fetoprotein (AFP) 
level and is an independent predictor for HCC-
specific OS and DFS [100, 101]. The serum 
level of Amphiregulin, a member of the epider-
mal growth factor family and one of the direct 
target genes of YAP/TAZ, is frequently elevated 
in HCC patients and may be used as a serologi-
cal biomarker of HCC [100]. Besides Amphi- 
regulin, it is now evident that YAP overexpres-
sion can induce the expression and secretion 
of many paracrine-acting factors including 
plasminogen activator inhibitor-1 (PAI-1), C-X-C 
motif chemokine ligand 13 (CXCL13), CXCL16 
during liver tumorigenesis. Amphiregulin and 
PAI-1 may play unique roles in liver tumorigen-
esis and therefore could serve as novel targets 
in HCC therapy [102-105]. Sohn et al. further 
extended these findings and identified a unique 
subgroup of HCC with silence of Hippo (SOH) 
signature. The SOH subgroup consists approxi-
mately 21% in the National Cancer Institute 
cohort, has a significantly poorer prognosis 
than non-SOH HCC patients. The SOH signature 
was an independent predictor of DFS on multi-
variate analysis [106]. 
YAP/TAZ has also played a critical role for epi-
thelioid hemangioendothelioma (EHE), a rare 
form of primary liver sarcoma. The chromo- 
somal translocations involving 1p36.3 and 
3q25, with formation of TAZ (WWTR1) - CAMTA1 
(calmodulin-binding transcription activator 1) 
gene fusion, has been identified in about 90% 
of EHE cases [107, 108]. The remaining 10% of 
EHE cases harbor YAP-TFE3 gene fusion [109]. 
CAMTA1 nuclear expression by immunohisto-
chemistry has been proven to be highly sensi-
tive and specific for the diagnosis of hepatic 
EHE, and could be used to differentiate hepatic 
EHE from its close mimic angiosarcoma [110]. 
In two recent studies, TAZ-CAMTA1 gene fusion 
is sufficient to drive EHE tumorigenesis by dys-
regulating YAP/TAZ signaling in a mouse model 
[111, 112]. 
Therapeutic perspective
Given its important role in tumorigenesis, tar-
geting Hippo-YAP signaling is a novel and attrac-
tive approach for cancer therapy. As the signal-
ing transducer and nexus of Hippo pathway, 
YAP/TAZ has been in the center for such devel-
opment. Few experimental prototype molecules 
have been discovered due to their ability to sup-
press YAP/TAZ activity. Verteporfin, the first 
photosensitizer approved for the treatment of 
age-related macular degeneration, was identi-
Hippo pathway in digestive system tumors
2501 Am J Cancer Res 2021;11(6):2495-2507
fied as a potent inhibitor of the physical interac-
tion between YAP with transcription factor 
TEAD. In a mouse model, Verteporfin signifi-
cantly suppressed YAP-induced hepatomegaly 
[113]. Song et al. identified CA3 through a small 
molecular screen that could potently inhibit 
YAP/TEAD transcriptional activity. CA3 inhibits 
esophageal adenocarcinoma cell growth both 
in vitro and in vivo [114]. Jiao et al. designed a 
VGLL4-mimicking peptide that could suppress 
gastric cancer growth through competing with 
YAP for TEAD interaction [53]. Drugs targeting 
the cellular receptors including G-protein-
coupled receptor (GPCR) [115, 116], epidermal 
growth factor receptor (EGFR) [117, 118] and 
vascular endothelial growth factor receptor 
(VEGFR) [119, 120] could also inhibit YAP/TAZ 
activity through an indirect manner.
Moroishi et al. revealed an unexpected function 
of Hippo pathway in modulating tumor immuno-
genicity. In tumor cells, deletion of LATS1/2 
leads to enhanced tumor-specific humoral 
and cellular immune responses, resulting in 
immune-mediated tumor cell elimination. 
Deletion of LATS1/2 also enhances tumor vac-
cine efficacy through adaptive immunity. These 
interesting findings raise the possibility of tar-
geting LATS1/2 kinase in cancer immunothera-
py [121]. Meanwhile, pharmacological targeting 
of MST1/2 kinase has resulted in the discovery 
of XMU-MP-1, a potent and selective inhibitor of 
MST1/2 kinase. XMU-MP-1 has demonstrated 
its in vivo efficacy to promotes liver and intesti-
nal regeneration and to attenuate acetamino-
phen-induced liver injury [122]. Searching for 
potent and specific small molecule kinase 
inhibitor targeting Mst1/2 and Lats1/2 kinases 
is therefore of great clinical relevance.
Conclusions
As an evolutionally conserved pathway, Hippo-
YAP signaling has played an important role in 
regulating cell proliferation, apoptosis and dif-
ferentiation from Drosophila to human. Hippo-
YAP signaling has been shown to extensively 
involve in intestinal stem cell reprogramming, 
intestinal and liver regeneration, and digestive 
system tumorigenesis. YAP/TAZ may function 
either as oncogene or tumor suppressor 
depending on the cellular context. Current stud-
ies have begun to reveal its complex multifac-
eted nature, as well as its complicated interplay 
with other conserved signaling pathways, such 
as the Wnt/β-catenin/APC pathway. It is of 
great clinical interest to develop pharmacologi-
cal molecules targeting Hippo-YAP signaling for 
personalized medicine on digestive system 
tumors.
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